Wavelength-Pharmaceuticals-Insert
X

Find Oncology Drugs in Phase I/II Clinical Development in SWEDEN

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BI-1206,Pembrolizumab

            Therapeutic Area: Oncology Product Name: BI-1206

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 21, 2020

            Details:

            BioInvent's lead pipeline candidate BI-1206 is a first-in-class monoclonal antibody that targets FcγRIIB - the only inhibitory Fcγ receptor that acts as a "brake" on the innate immune system - to unleash antibody-mediated reactivation of the immune response against cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MIV-818

            Therapeutic Area: Oncology Product Name: MIV-818

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 25, 2020

            Details:

            European Medicines Agency (EMA), has granted orphan medicinal product designation in the EU for MIV-818 for the treatment of patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BI-1206,Pembrolizumab

            Therapeutic Area: Oncology Product Name: BI-1206

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 23, 2020

            Details:

            The objective of this trial is to explore the safety and tolerability profile of the combination of BI-1206 with KEYTRUDA, to characterize the pharmacokinetic/pharmacodynamic (PK/PD) profile and to determine the recommended dose of BI-1206 when combined with KEYTRUDA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nidanilimab

            Therapeutic Area: Oncology Product Name: CAN04

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 22, 2020

            Details:

            The antibody CAN04 binds IL1RAP with high affinity and functions through both Antibody-Dependent Cellular Cytotoxicity (ADCC) and blockade of interleukin-1 (IL-1) signaling.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ilixadencel,Pembrolizumab

            Therapeutic Area: Oncology Product Name: Intuvax

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 16, 2020

            Details:

            The publication reports final data analysis from ilixadencel study in patients with Gastrointestinal Stromal Tumors. The trial met the primary endpoint showing that ilixadencel in combination with different TKIs had a favorable safety profile with no side-effects.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MIV-818

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 06, 2020

            Details:

            U.S FDA has granted orphan drug designation (ODD) to MIV-818 for the treatment of patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MIV-818

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 06, 2020

            Details:

            The U.S FDA has granted orphan drug designation to MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects, for the treatment of hepatocellular carcinoma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Troxacitabine

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 29, 2020

            Details:

            This designation can give access to several incentives, including protocol assistance, the EU centralized authorization procedure and reduced regulatory fees and10-year market exclusivity in the EU.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BI-1206,Rituximab

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 14, 2020

            Details:

            In the Phase I part of the trial, three separate responses have been observed across different subtypes of NHL at doses of BI-1206. A patient in the 70mg cohort has achieved a complete response.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Melphalan Flufenamide,Dexamethasone

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 24, 2020

            Details:

            In the O-12-M1 study, patients receiving melflufen plus dexamethasone experienced an overall response rate of 31%, a median duration of response of 8.4 months, and overall survival of 20.7 months.

            PharmaCompass